PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Gross profit growth of 12.50% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
-29.39%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-29.39%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-30.95%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-22.58%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-22.58%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
7.95%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
7.95%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-7.95%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
91.14%
OCF/share CAGR of 91.14% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
75.06%
5Y OCF/share growth exceeding 1.5x Healthcare median of 16.05%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
-16.88%
Negative 3Y OCF/share CAGR while Healthcare median is 8.38%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-109.23%
Negative 10Y net income/share CAGR vs. Healthcare median of 31.85%. Seth Klarman might see a fundamental problem if peers maintain growth.
62.10%
5Y net income/share CAGR > 1.5x Healthcare median of 29.66%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-51.96%
Negative 3Y CAGR while Healthcare median is 19.92%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-71.08%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-53.15%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-63.40%
Negative 3Y equity/share growth while Healthcare median is -5.12%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Asset growth of 1.71% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-7.41%
Negative BV/share change while Healthcare median is -0.18%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-6.71%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
37.48%
R&D growth of 37.48% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
21.30%
SG&A growth of 21.30% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.